European Journal of Health Economics

Article	Citations
Education and medication use later in life and the role of intelligence	87
Beyond 10-year lead-times in EQ-5D-5L: leveraging alternative lead-times in willingness-to-accept questions to capture preferences for worse-than-dead states and their implication	69
Correction to: Geographic distribution of physicians in Portugal	42
Pragmatic randomized controlled trial comparing a complex telemedicine-based intervention with usual care in patients with chronic conditions	30
Psychometric properties and general population reference values for PROMIS Global Health in Hungary	30
The hidden cost of sophistication: economic complexity and obesity	26
Comparing the measurement properties of the EQ-5D-Y-3L, EQ-5D-Y-5L and CHU9D in children and adolescents: a measurement property study	25
Cost-effectiveness of transcatheter aortic valve implantation in patients at low surgical risk in France: a model-based analysis of the Evolut LR trial	25
Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries	25
Patient-level cost analysis of subfertility pathways in the Dutch healthcare system	24
Should Scotland provide genome-wide sequencing for the diagnosis of rare developmental disorders? A cost-effectiveness analysis	22
Prescription opioids and economic hardship in France	21
Expensive today but cheaper tomorrow: lifetime costs of an active middle ear implant compared to alternative treatment options	21
Workload and short sickness absences in a cohort of Finnish hospital employees	21
Nothing about us, without us? A reflection on and call for involving children in the process of valuing child health	21
Cost awareness among intensivists in their daily clinical practice: a prospective multicentre study	20
Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan	20
From test to rest: evaluating socioeconomic differences along the COVID-19 care pathway in the Netherlands	19
Replay to: Comparison of EQ-5D-5 L and EORTC QLU-C10D utilities in gastric cancer patients	19
Setting incentives right with long-term risk adjustment	19
Primary care services and emergency department visits in blended fee-for-service and blended capitation models: evidence from Ontario, Canada	19
Comparing EQ-5D-5L and SF-6Dv2 utilities with QLU-C10D utilities in hematologic cancer patients	18
Trends in NICE technology appraisals of non-small cell lung cancer drugs over the last decade	18
Health-related quality of life in patients with alcohol use disorder: comparing instruments and mapping from clinical measures to preference-based measures	18
Economic assessment of abemaciclib for the adjuvant treatment of luminal HER2- breast cancer from the perspective of the Spanish health system	18

Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma	17
Informing decisions in light of parameter uncertainty – an economic evaluation of the adjuvanted recombinant herpes zoster vaccine in Sweden	17
The causal effect of catastrophic health expenditure on poverty in Poland	16
The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands	16
Breaking the rules: decision-making under absolute resource constraints	16
Multinational stakeholder engagement to inform future development and refinement of the EuroQol toddler and infant populations (EQ-TIPS)	16
On spillovers in economic evaluations: definition, mapping review and research agenda	16
Correction: AOTMiT reimbursement recommendations compared to other HTA agencies	15
Antivirals to prepare for surges in influenza cases: an economic evaluation of baloxavir marboxil for the Netherlands	15
Benefits beyond health in the willingness to pay for a quality-adjusted life-year	15
Do EQ-5D-Y-3L value sets have common properties, and how do they compare to EQ-5D-5L value sets?	15
The trade-off between health system resiliency and efficiency: evidence from COVID-19 in European regions	15
Can competition improve hospital quality of care? A difference-in-differences approach to evaluate the effect of increasing quality transparency on hospital quality	15
Generating EQ-5D-5L health utility scores from BASDAI and BASFI: a mapping study in patients with axial spondyloarthritis using longitudinal UK registry data	15
Hospital resource utilisation from HPV-related diseases in England: a real-world cost analysis	14
Costs attributable to hypercholesterolemia in a single period and over the life cycle	14
Analyzing nurses’ decisions to leave their profession—a duration analysis	14
How perceptions of bone marrow donation costs affect donation behavior: survey evidence from a large donor registry	14
Is next generation sequencing for the diagnosis of rare diseases worth its cost? A user-based approach to valuation	14
Estimating loss in capability wellbeing in the first year of the COVID-19 pandemic: a cross-sectional study of the general adult population in the UK, Australia and the Netherlands	13
The social value of gambling: surplus estimates by gambling types for France	12
The goal of risk equalization in regulated competitive health insurance markets	12
Is ultra-hypo-fractionated radiotherapy more cost-effective relative to conventional fractionation in treatment of prostate cancer? A cost–utility analysis alongside a randomized HYPO-RT-PC trial	12
Time value of informal care of people with alzheimer’s disease in Spain: a population-based analysis	12
Healthcare costs of foodborne diseases in the United States: an analysis using electronic health records	12
Adverse selection and consumer inertia: empirical evidence from the Dutch health insurance market	12
Sex differences in care complexity and cost of cardiac-related procedures as a basis for improving hospital payments systems	11
The impact of ambulatory care spending, continuity and processes of care on ambulatory care sensitive hospitalizations	11
A principled approach to non-discrimination in cost-effectiveness	11
The impacts of working from home on individual health and well-being	11
Changes in spending, quality indicators, and provider experiences following the introduction of a population-based payment model in dutch primary care: a mixed methods evaluation	11
Economic value of diastasis repair with the use of mesh compared to no intervention in Italy	11
Does prescribing apixaban or rivaroxaban versus warfarin for patients diagnosed with atrial fibrillation save health system costs? A multivalued treatment effects analysis	11
Modeling European health systems: an ideal chain of services	10
Do mobile hospital teams in residential aged care facilities increase health care efficiency: an evaluation of French residential care policy	10
Pharmacy cost groups for the German morbidity-based risk compensation scheme	10
The attractiveness of jobs in the German care sector: results of a factorial survey	10
Does chronic disease coverage for outpatient care affect healthcare utilization and expenditures in China? Evidence from an administrative claim dataset	10
Estimating QALYs in adults with cerebral palsy: mapping the San Martin scale to the EQ-5D-5L for economic evaluation	10
A comprehensive review of official discount rates in guidelines of health economic evaluations over time: the trends and roots	10
Demographic and health impacts of women’s bodily autonomy: switching prescription requirements for emergency contraceptives	10
Modeling the potential efficiency of a blood biomarker-based tool to guide pre-hospital thrombolytic therapy in stroke patients	9
Preferences for COVID-19 epidemic control measures among French adults: a discrete choice experiment	9
Scales and size-quality outcomes in adult learning disability residential care: evidence from the UK	9
Tenders for generics and biosimilars: a challenging purchasing policy	9
Significant healthcare burden and life cost of spinal muscular atrophy: real-world data	9
Valuation of the EQ-5D-3L in Jordan	9
The ACA Medicaid expansions and abortion rates among young adults	9
Validation of the PAM-13 instrument in the Hungarian general population 40 years old and above	9
Do we care about high-cost patients? Estimating the savings on health spending by integrated care	9

How tax structures for retail cannabis shape cannabis use among youth and young adults: evidence from a volumetric choice experiment	9
Does medial tourism promote growth in healthcare sector?	9
Alcohol prices, the April effect, and the environment, in violence-related injury in England and Wales	9
Change in healthcare resource use and associated costs of patients with metastatic lung cancer between 2013 and 2021: an observational study from the French national health data system	9
Determinants of willingness to pay for health services: a systematic review of contingent valuation studies	8
Costs of productivity loss up to two years after ischaemic stroke	8
Supply-side solutions targeting demand-side characteristics: causal effects of a chronic disease management program on adherence and health outcomes	8
The pass-through of excise taxes to market prices of heated tobacco products (HTPs) and cigarettes: a cross-country analysis	8
Personnel shortages and the provision of long-term care: an empirical analysis of German nursing homes	8
Assessment of health state utilities associated with adult and pediatric acid sphingomyelinase deficiency (ASMD)	8
Obtaining preference scores for an abbreviated self-completion version of the Teen-Addiction Severity Index (ASC T-ASI) to value therapy outcomes of systemic family interventions: a discrete choice ex	8
The link between physician motivation and care	8
Cost-utility of cochlear implantation in single-sided deafness and asymmetric hearing loss: results of a randomized controlled trial	8
Cost-effectiveness of two online interventions supporting self-care for eczema for parents/carers and young people	8
How are patient inputs considered in HTA? A thematic document analysis of NICE ultra-rare disease appraisals	8
Survival analysis of cancer patients in Portugal following the reference centre model implementation	8
Economic evaluation on dental caries preventive interventions for Australian children using a priority-setting approach	8
Challenges for health systems seeking to embrace virtual health care for population health	8
Economics of hypothalamic obesity in patients with craniopharyngioma and other rare sellar/suprasellar tumors	8
Seeking efficiency gains outside drugs and diagnostics	7
Impact of the introduction of the AMNOG law on launch delays of new drugs in Germany: a comment	7
Recovery of suspended reimbursements of high-cost drugs subjected to monitoring registries and negotiated agreements (MEAs): a tool for governance and clinical appropriateness in the Italian reality	7
Referring physicians' intention to use hospital report cards for hospital referral purposes in the presence or absence of patient-reported outcomes: a randomized trial	7
Disclosing the ‘Big C’: what does cancer survivorship signal to employers?	7
Modeling European health systems: a theoretical exercise	7
Health state utilities associated with X-linked retinitis pigmentosa (XLRP)	7
Assessing Taiwan’s pay-for-performance program for diabetes care: a cost–benefit net value approach	7
Healthcare costs of diabetic foot disease in Italy: estimates for event and state costs	7
Trends and drivers of pharmaceutical expenditures from systemic anti-cancer therapy	7
The health and long-term care costs in the last year of life in The Netherlands	7
Inpatient care utilisation and expenditure associated with objective physical activity: econometric analysis of the UK Biobank	7
Does health technology assessment compromise access to pharmaceuticals?	7
Self-interest, positional concerns and distributional considerations in healthcare preferences	7
Does diagnostic testing always decrease antibiotics prescriptions?	7
Unravelling heterogeneity in efficiency measurements: a case study of public hospitals in Spain	7
Psychometric performance of proxy-reported EQ-5D youth version 5-level (EQ-5D-Y-5L) in comparison with three-level (EQ-5D-Y-3L) in children and adolescents with scoliosis	7
Obesity and metabolic state are associated with increased healthcare resource and medication use and costs: a Finnish population-based study	6
Ex ante evaluation of risk adjustment models for prospective provider payment: a conceptual framework and empirical application	6
A hearing bolt-on item increased the measurement properties of the EQ-5D-5L in a community-based hearing loss screening program	6
The performance of the EQ-HWB-S as a measure of quality-of-life of caregivers in families that have experienced adverse events	6
Comparing EQ-5D-5L, PROPr, SF-6D and TTO utilities in patients with chronic skin diseases	6
Long-term costs associated with healthcare use of people with cancer in Scotland	6
Time preferences and COVID-19 vaccination uptake	6
The effect of displaying laboratory test prices on physicians’ ordering behaviour: a systematic review of European studies	6
One week versus three to five weeks of plaster cast immobilization for nonreduced distal radius fractures, a cost effectiveness analysis embedded in a stepped wedge cluster randomized controlled trial	6
Generating EQ-5D-3L health utility scores from the Edinburgh Postnatal Depression Scale: a perinatal mapping study	6
A cross-country comparison of the psychometric performance of SF-6Dv2 and EQ-5D-5L	6
EQ-5D-5L Portuguese population norms	5
Assessing the economic burden of complicated urinary tract infection: A systematic literature review	5
Critical issues with methods and results interpretation at validating the EQ-5D-5L and QLU-C10D utilities in gastric cancer patients	5
Willingness to pay for a quality adjusted life year across different time horizons: direct elicitation in Quebec	5
The societal cost of ‘unwanted’ loneliness in Spain	5
Long-term effectiveness and cost-effectiveness of testing for alemtuzumab antidrug antibodies to guide treatment in multiple sclerosis: a modelling study	5
A critical review of the use of R2 in risk equalization research	5
A cost-of-illness study of Behçet syndrome in Italy	5
Valuation of EQ-5D-5L health states from cancer patients’ perspective: a feasibility study	5
Validity and responsiveness of EQ-5D-Y in children with haematological malignancies and their caregivers	5
Mapping of the EORTC QLQ-LC43 to EQ-5D-5 L index in patients with lung cancer: comparison of traditional regression models with machine learning technique	5
Cost-effectiveness and cost-utility analysis of a nurse-led, transitional care model to improve care coordination for patients with cardiovascular diseases: results from the “Cardiolotse” study	5
Cost-effectiveness analysis of the covered endovascular reconstruction of the aortic bifurcation versus kissing stents and open surgical repair for the treatment of aorto-iliac occlusive disease	5
Total costs of different lines of treatment in diffuse large B-cell lymphoma in Denmark – a real-world data analysis	5
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy	5
Cost-effectiveness of the MitraClip device in German heart failure patients with secondary mitral regurgitation	5
Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease	5
Does opt-out legislation crowd out living organ donations? A cross-country study	5
New evidence on supplier-induced demand in China’s public tertiary hospitals: is the cost of hospitalization higher in the off-season?	5
Were we happy and we didn’t know it? A subjective dynamic and financial assessment pre-, during and post-COVID-19	5
Economic burden of eosinophilic esophagitis in the first year after diagnosis in Spain: A direct medical cost analysis	5
Risk, time preferences, trustworthiness and COVID-19 preventive behavior: evidence from France	5
Correction: Lifetime direct healthcare costs of treating colorectal cancer: a systematic review	5
Translating the EORTC CAT core and the QLQ-C30 to the EQ-5D-5L in patients with metastatic breast cancer: A comparison of direct and indirect mapping algorithms	5
Breaking the habit: a systematic review of the cost-effectiveness of non-pharmacological and combined interventions for smoking cessation in Europe	5
Productivity costs associated with premature deaths due to acute myocardial infarction in Spain: analysis from 2013 to 2022	5
On absolute socioeconomic health inequality comparisons	5
Making the rules make sense: valuation of constrained resources	5
Estimating surgery, radiotherapy and systemic anti-cancer therapy treatment costs for cancer patients by stage at diagnosis	4
Routine measurement in low back pain; towards a pragmatic patient-reported productivity cost outcome measurement using the institute for medical technology assessment productivity cost questionnaire	4
Costs associated with insufficient physical activity in Germany: cross-sectional results from the baseline examination of the German national cohort (NAKO)	4
Comparison of EQ-5D-5L and EORTC QLU-C10D utilities in gastric cancer patients	4
Broadening sources of finance for health promotion and disease prevention: Smart capacitating investment	4

The handling of missing data in trial-based economic evaluations: should data be multiply imputed prior to longitudinal linear mixed-model analyses?	4
Assessing the relation between financial performance and long-term bank loan interest rates for healthcare providers in the Netherlands: a panel data analysis	4
Health technology assessment criteria as drivers of coverage with managed entry agreements: a case study of cancer medicines in four countries	4
A systematic review of the cost-effectiveness of interventions to increase cervical cancer screening among underserved women in Europe	4
Shaping a suitable EU HTA dossier template: why the German template is not fit for purpose	4
Complexities of health and acceptance of electronic health records for the Austrian elderly population	4
A state-level analysis of macro-level factors associated with hospital readmissions	4
Early start of anti-dementia medication is associated with lower health and social care costs in Alzheimer´s patients: a Finnish nationwide register study	4
Willingness to pay for measures to increase use of active school transport	4
Public versus private healthcare systems in the OECD area– a broad evaluation of performance	4
Does a free maternity policy in Kenya work? Impact and cost–benefit consideration based on demographic health survey data	4
A novel mathematical model for prioritization of individuals to receive vaccine considering governmental health protocols	4
Comparison of four approaches in eliciting health state utilities with SF-6Dv2	4
Cost-effectiveness of 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer: preplanned cost-effectiveness analysis of the JFMC37-0801 study	4
Comparison of the EQ-5D-Y and the CHU-9D instruments in a general child population based on self-reports and proxy-reports	4
Cancer-specific utility: clinical validation of the EORTC QLU-C10D in patients with glioblastoma	4
Future medical and non-medical costs and their impact on the cost-effectiveness of life-prolonging interventions: a comparison of five European countries	4
Variation in patient-reported outcomes after total hip replacement across ten high-volume hospitals in Germany: results from a multicenter, prospective, longitudinal Cohort Study	4
Migration-related determinants of health-care service utilization among persons with a direct migration background in Germany: an exploratory study based on the German Socio-Economic Panel (SOEP)	4
Loss aversion in EQ-5D-Y-3L: does it explain differences in willingness to trade-off life years in adults and children?	4
Out-of-pocket costs sustained in the last 12 months by cancer patients: an Italian survey-based study on individual expenses between 2017 and 2018	4
The effect of telephone health coaching and remote exercise monitoring for peripheral artery disease (TeGeCoach) on health care cost and utilization: results of a randomized controlled trial	4
Informal care at old age at home and in nursing homes: determinants and economic value	4
Measuring the acceptability of EQ-5D-3L health states for different ages: a new adaptive survey methodology	4
The EORTC QLU-C10D: the Hong Kong valuation study	3
Test-retest reliability of the Online Elicitation of Personal Utility Functions (OPUF) approach for valuing the EQ-HWB-S	3
Are there differences in health state preferences between urban and rural respondents? a comparison using time trade-off and discrete choice experiment	3
Is there a link between health care utilisation and subjective well-being? An exploratory study among older Danes	3
Population preferences for non-pharmaceutical interventions to control the SARS-CoV-2 pandemic: trade-offs among public health, individual rights, and economics	3
Economic and human burden attributable to antimicrobial resistance in Spain: a holistic macro-estimation of costs	3
The EQ-5D-3L valuation study for Bermuda: using an on-line EQ-VT protocol	3
Short- and intermediate-term impact of DTC telemedicine consultations on subsequent healthcare consumption	3
Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L descriptive systems and utilities in atopic dermatitis	3
TF-TAVI and SAVR post-procedural complications in Germany 2021/2022 – impact on healthcare resource consumption	3
The common interests of health protection and the economy: evidence from scenario calculations of COVID-19 containment policies	3
Cost-effectiveness analysis of procalcitonin and lung ultrasonography guided antibiotic prescriptions in primary care	3
Health shocks and health behavior: a long-term perspective	3
Out-of-pocket expenses of patients with inflammatory bowel disease: a comparison of patient-reported outcomes across 12 European countries	3
Does the abolition of copayment increase ambulatory care utilization?: a quasi-experimental study in Germany	3
Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin’s lymphoma	3
Ageing and health care expenditures: the importance of age per se, steepening of the individual-level expenditure curve, and the role of morbidity	3
Value drivers of development stage biopharma companies	3
“COVID-19 and income inequality in OECD countries:” A methodological comment	3
Impact of Long COVID on productivity and informal caregiving	3
Financial risk allocation and provider incentives in hospital–insurer contracts in The Netherlands	3
Exploring non-iterative time trade-off methods for valuation of EQ-5D-5L health states	3
Cost-effectiveness of Mavacamten for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy using a French healthcare perspective	3
Population norms for the EQ-5D-5L for Hungary: comparison of online surveys and computer assisted personal interviews	3
Comparing the measurement properties of the EQ-5D-5 L, SF-6Dv2, QLU-C10D and FACT-8D among survivors of classical Hodgkin’s lymphoma	3
Vaccination or NPI? A conjoint analysis of German citizens' preferences in the context of the COVID-19 pandemic	3
Age, morbidity, and time to death: End-of-life expenditures on health care for the young-old population	3
Are costs derived from diagnosis-related groups suitable for use in economic evaluations? A comparison across nine European countries in the European Healthcare and Social Cost Database	3
What remains after the money ends? Evidence on whether admission reductions continued following the largest health and social care integration programme in England	3
Nexus among health expenditures, ICTs and sustainable economic growth: Insights from South Asian Nationals health and economic issues	3
The impact of parastomal hernia on quality of life using data from the CIPHER prospective cohort study	3
Population normative data for OxCAP-MH capability scores	3
The economic burden of asthma in Italy: evaluating the potential impact of different treatments in adult patients with severe eosinophilic asthma	3
United Kingdom value set for the functional assessment of cancer therapy eight dimension (FACT-8D) preference-based quality of life instrument	3
Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France	3
Lifetime direct healthcare costs of treating colorectal cancer: a systematic review	3
Time and lexicographic preferences in the valuation of EQ-5D-Y with time trade-off methodology	2
Country-level effects of diagnosis-related groups: evidence from Germany’s comprehensive reform of hospital payments	2
Pembrolizumab vs. chemotherapy in the first-line setting of PD-L1 ≥ 50% metastatic non-small cell lung cancer: a real-world cost-effectiveness analysis	2
Willingness to pay for health gains from an international integrated early warning system for infectious disease outbreaks	2
The economic burden of idiopathic pulmonary fibrosis in Australia: a cost of illness study	2
Estimating the willingness-to-pay to avoid the consequences of foodborne illnesses: a discrete choice experiment	2
A Spanish value set for the SF-6D based on the SF-12 v1	2
The economic burden of mental disorders: results from the Netherlands mental health survey and incidence study-2	2
Does timing matter? The role of health information shocks in measuring willingness to pay	2
Monetary value of health—a practical decision-making framework combining equity considerations and WTP	2
Using machine learning to estimate health spillover effects	2
To what extent does the use of crosswalks instead of EQ-5D value sets impact reimbursement decisions?: a simulation study	2
Incentivizing adherence to pre-exposure prophylaxis for HIV prevention: a randomized pilot trial among male sex workers in Mexico	2
Burden of myelodysplastic syndromes: a systematic literature review of economic burden	2
Far more than a shot in the arm: Vaccines and consumer spending	2
Nonprofit behavior altered by monetary donations: evidence from the U.S. hospice industry	2
Cost-effectiveness of TAVI in the United Kingdom: a long-term analysis based on 4-year data from the Evolut Low Risk Trial	2
How a nation’s well-being influences its health profile: an analysis of critical indicators	2
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations	2
Mapping functions for the PHQ-9 and GAD-7 to generate EQ-5D-3L for economic evaluation	2
Cost-effectiveness of the MitraClip device in secondary mitral regurgitation: comment upon the article by Estler et al.	2
Trends in physical and mental health needs across generations in Australia	2
Cost effectiveness of a GP delivered medication review to reduce polypharmacy and potentially inappropriate prescribing in older patients with multimorbidity in Irish primary care: the SPPiRE cluster	2
Cost analysis of transthyretin amyloid cardiomyopathy in heart failure patients with preserved ejection fraction in Spain	2
The formal care costs of dementia: a longitudinal study using Swedish register data	2
A model-based cost-effectiveness analysis of prescribing by dietitians and therapeutic radiographers in England	2
Completing the time trade-off with respondents who are older, in poorer health or with an immigrant background in an EQ-5D-5L valuation study	2
Does uptake of specialty care affect HRQoL development in COPD patients beneficially? A difference-in-difference analysis linking claims and survey data	2
Dividend policy issues in the European pharmaceutical industry: new empirical evidence	2
Changes in disposable income of Polish households and growing trends in alcohol mortality	2
Tough versus soft regulations to promote generic medications in Italy	2
Does competition improve hospital performance: a DEA based evaluation from the Netherlands	2
Catastrophic household expenditure associated with out-of-pocket payments for dental healthcare in Spain	2
The causal effect of early retirement on medication use across sex and occupation: evidence from Danish administrative data	2
The added value of the cognition, dining, gastrointestinal problems, sleep and tiredness bolt-on dimensions to the EQ-5D-5L in patients with coeliac disease	2